List of Fabior drug patents
Fabior is owned by Mayne Pharma.
Fabior contains Tazarotene.
Fabior has a total of 3 drug patents out of which 0 drug patents have expired.
Fabior was authorised for market use on 11 May, 2012.
Fabior is available in aerosol, foam;topical dosage forms.
Fabior can be used as topical treatment of acne vulgaris in patients 12 years of age or older.
The generics of Fabior are possible to be released after 24 February, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(6 years from now) | |
| US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(6 years from now) | |
| US8808716 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(6 years from now) | |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 11 May, 2012
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM;TOPICAL
FABIOR family patents
5
United States
2
Australia
2
Japan
1
Canada
1
Mexico
1
Singapore
1
Brazil
1
China
1
South Africa
1
EA
1
Denmark
1
Israel
1
Portugal
1
Spain
1
Poland
1
Korea, Republic of
1
Chile
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic